Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna (MRNA) has reiterated its target of up to 10% revenue growth in 2026, supported by a strategy to build a large ...

Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Stéphane Bancel, Moderna’s ...